Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2
Date
2012Author
Kosmidis, Paraskevas A.Syrigos, K.
Kalofonos, H. P.
Dimopoulos, M. A.
Skarlos, Dimosthenis V.
Pavlidis, Nicholas
Boukovinas, I.
Bafaloukos, Dimitrios
Pectasides, Dimitrios
Bacoyiannis, Charalambos
Fountzilas, George
Source
Anticancer ResearchVolume
32Issue
1Pages
175-181Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Aim: The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2. Patients and Methods: The patients were randomized to receive either oral vinorelbine 60 mg/m 2 on days I, 8, 15 every 4 weeks for 4 cycles (group A) or paclitaxel 90 mg/m 2 intravenously for 1 h on days 1, 8, 15 every 4 weeks for a total of 4 cycles (group B). Results: Among the 74 eligible patients (36 in arm A and 38 in arm B) in arm A, two (6%) had a partial response (95% Cl, 0.7-18.7) and 5 (14%) had stable disease (95% CI, 4.7-29.5). In arm B, five (13%) had a partial response (95% CI, 4.4-28.1) and 7 (18%) had stable disease (95% CI, 7.7-34.3). No significant difference was found in terms of clinical benefit between the two groups after two cycles of treatment except for appetite in favour of paclitaxel (p=0.01). Median survival was 3.1 months (95% CI, 2.2-4.0) for arm A and 5.1 months (95% CI, 2.7-7.6) for arm B (p=0.95). Toxicity was mild and only alopecia was more profound in the patients of arm B (p=0.008). Conclusion: No significant difference was found in clinical benefit between PS:2 NSCLC patients treated with either vinorelbine or paclitaxel.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases
Voulgaris, E.; Pentheroudakis, George; Pappa, L.; Bafa, M.; Goussia, Anna; Dalezis, P.; Tsombanidou, C.; Geromichalos, G.; Papageorgiou, A.; Koutsilieris, M.; Malamou-Mitsi, Vassiliki D.; Pavlidis, Nicholas (2011)Purpose: To study the phenomenon of positive urine cytology in patients with lung cancer in the absence of obvious urothelial metastases. Patients and methods: 150 patients with small (SCLC) and non-small cell lung cancer ...
-
Article
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
Briassoulis, E. Ch; Samantas, E.; Kalofonos, H. P.; Skarlos, Dimosthenis V.; Makatsoris, T.; Christodoulou, C.; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2005)The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. ...
-
Article
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Peccatori, Fedro A.; Azim, Hatem A.; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas; Kesic, V.; Pentheroudakis, George (2013)